Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients

Transpl Int. 2022 Mar 22:36:10357. doi: 10.3389/ti.2022.10357. eCollection 2022.

Authors

Judith Schimpf¹, Tamara Davidovic¹, Armin Abbassi-Nik¹, Hannelore Sprenger-Mähr¹, Karl Lhotta^{1

2}, Emanuel Zitt^{1

2

3}

Affiliations

¹ Department of Internal Medicine 3 (Nephrology and Dialysis), Academic Teaching Hospital LKH Feldkirch, Feldkirch, Austria.
² Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
³ Agency for Preventive and Social Medicine (aks), Bregenz, Austria.

No abstract available

Keywords: Ad26COVS1; Covid-19; Sars-CoV-2; heterologous vaccination; kidney transplantation.

Publication types

Letter

MeSH terms

Ad26COVS1
Antibodies, Viral
Antibody Formation
COVID-19* / prevention & control
Humans
Kidney Transplantation*
SARS-CoV-2
Transplant Recipients
Vaccination
Vaccines, Synthetic
mRNA Vaccines

Substances

Ad26COVS1
Antibodies, Viral
Vaccines, Synthetic
mRNA Vaccines